The effect of fluconazole on the susceptibility of Candida isolates recovered from women infected with human immunodeficiency virus (HIV) was evaluated in a randomized, double-blind, placebo-controlled trial. Women with CD4 + cell counts of р300 cells/mm 3 received either fluconazole (200 mg/week) or placebo as prophylaxis. The antifungal susceptibility of specimens was evaluated. One patient who received fluconazole and 2 patients assigned to placebo had Candida albicans isolates recovered that were resistant to fluconazole (MIC, у64 mg/ mL). Eleven patients assigned fluconazole and 4 patients assigned placebo had non-albicans Candida strains (all Candida glabrata) recovered that were resistant to fluconazole. There was significant azole cross-resistance among the non-albicans Candida species isolates. Although the rate of azole resistance did not significantly increase after fluconazole prophylaxis, there was a trend toward more in vitro azole resistance in C. glabrata isolates from patients assigned fluconazole. Moreover, the majority of resistant vaginal isolates of Candida species were recovered after initiation of open-label fluconazole use.
Fluconazole is frequently used for the treatment of mucocutaneous candidiasis in patients with AIDS [8] [9] [10] [11] . In addition, either daily or intermittent doses of fluconazole have been shown to be effective in preventing mucosal candidiasis in patients with AIDS [12] [13] [14] [15] [16] [17] . The routine use of fluconazole as primary or secondary prophylaxis against fungal infections remains controversial because of cost, drug interactions, and risk of antifungal resistance [12, 18] .
Despite the numerous reports of isolation of azoleresistant strains of Candida species from patients with refractory mucosal candidiasis, only a few longitudinal prospective studies have evaluated the antifungal susceptibility of Candida isolates recovered from HIV-positive patients receiving long-term therapy with fluconazole [19] .
We recently reported the results of a double-blind, randomized, placebo-controlled trial of fluconazole (200 mg per week) for the prevention of mucosal candidiasis in HIVinfected women with CD4 ϩ cell counts of р300 cells/mm 3 [13, 20] . The main findings were that (1) weekly doses of fluconazole were effective in preventing symptomatic oropharyngeal and vaginal candidiasis during a median follow-up of 29 months, and (2) Candida species recovered from vaginal surveillance cultures varied by treatment group, with weekly doses of fluconazole producing a persistent decrease in the isolation of Candida albicans and an increase in the recovery of nonalbicans Candida species.
In the present study, we extended the findings of our initial report by evaluating the in vitro antifungal susceptibility patterns of the fungal isolates and the incidence of cross-resistance with other azoles.
METHODS

Study design.
The enrollment criteria, treatment regimens, and characteristics of the women in the Women's Fungal Study of the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA; study number 010) are described in detail in the study's primary report [13] . In brief, eligible women were randomly assigned to receive either fluconazole (200 mg per week) or placebo. Open-label daily fluconazole for prophylaxis was permitted after 2 episodes of oropharyngeal or vaginal candidiasis or 1 episode of esophageal candidiasis (prophylaxis failure). Thus, the study compared the following 2 treatment strategies: (1) weekly administration of fluconazole until prophylaxis failure, when fluconazole at a dosage of 100 mg per day could be prescribed at the clinician's discretion, and (2) administration of placebo until prophylaxis failure, when daily fluconazole could be prescribed at the clinician's discretion. In addition, topical or systemic antifungal agents were allowed for treatment of acute episodes of mucosal candidiasis and were selected according to the clinician's preference.
The resistance substudy (CPCRA 029) opened to enrollment 1 year after the main study began and was conducted from March 1993 through November 1995. Following substudy enrollment, vaginal specimens were obtained at the scheduled 3-month follow-up visits and submitted for analysis. In addition, isolates obtained to confirm acute episodes of candidiasis were also evaluated.
Microbiology. Clinical specimens were obtained by culture swabs and plated on Sabouraud dextrose agar (Difco). Yeast were identified as C. albicans on the basis of germ tube and chlamydospore formation. If the yeast isolates produced no germ tubes, they were then submitted for standard testing to identify the genus and species of yeast (API 20C; bioMérieux).
The in vitro susceptibility to 5 antifungal agents was evaluated (fluconazole, clotrimazole, itraconazole, flucytosine, and amphotericin B). Testing was performed using of the microbroth dilution method and the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) [21] .
Interpretive breakpoints were based on recent recommendations from the NCCLS [21] . Fluconazole resistance was defined by an MIC of у64 mg/mL; susceptibility, by an MIC of р8 mg/ mL; and dose-dependent susceptibility (DD-S), by MICs of 16-32 mg/mL. Corresponding MIC breakpoints for itraconazole and clotrimazole were р0.125 mg/mL (susceptible), 0.25-0.5 mg/ mL (intermediate), and у1.0 mg/mL (resistant). Amphotericin B resistance was defined by an MIC of у2.0 mg/mL.
Statistical analysis. Primary analyses were performed on isolates from surveillance specimens collected every 3 months during follow-up visits. In these analyses, patients may have had multiple isolates tested. In the analyses referred to as "per patient," each patient was classified according to the highest MIC observed during follow-up. Median MICs are cited, and the Wilcoxon test was used to compare the distribution of the maximum MICs observed for each organism during follow-up for patients in both groups. Fisher's exact test was used to compare the percentage of patients who had at least 1 isolate with an MIC of у64 mg/mL (fluconazole-resistant) and 1 with an MIC of у16 mg/mL (DD-S).
In the analyses referred to as "per isolate," MICs of each isolate are summarized. For cultures that yielded mixed isolates, each isolate was considered separately. These descriptive analyses do not account for the correlation between multiple isolates for the same patient.
Both intention-to-treat and "on treatment" analyses were performed. For the former, patients were counted in the group to which they were randomized (fluconazole or placebo), even if they had discontinued taking the blinded study drug before enrolling in the resistance substudy. For the latter, patients were classified according to whether they were receiving blinded antifungal therapy or open-label fluconazole at the time the culture specimen was obtained. Patients who discontinued blinded medication and who did not begin therapy with open-label fluconazole were excluded from these analyses.
The concordance of in vitro resistance data for other azoles was also assessed with use of rank correlation and by comparison of agreement in 3 categories (susceptibility, DD-S, or resistance). The rank correlation analysis was based on the reported MIC.
RESULTS
Study Population and Blinded Treatment Status
The resistance substudy included 173 of the 323 patients enrolled in the CPCRA 010 study. These patients were enrolled by 9 of the 14 units that participated in the main study. Char- acteristics of the women in both groups were similar at the time of randomization (table 1) .
Patients were enrolled in the substudy an average of 10 months after randomization to the main study and were observed for an additional 19 months. As noted in table 1, 11 (12.1%) of the women assigned fluconazole and 28 (34.1%) of the women assigned placebo had at least 1 mucosal candidiasis event between randomization and enrollment in the substudy. After enrollment in the substudy, an additional 16 patients (18%) in the fluconazole group and 17 (21%) in the placebo group began taking open-label fluconazole. Thus, a total of 21 women (23%) assigned fluconazole and 26 women (32%) assigned placebo used open-label fluconazole during the followup period of the study. The use of open-label fluconazole represented 5% of the follow-up for those assigned blinded fluconazole and 10% of follow-up for those assigned placebo.
Surveillance Cultures
Three women in each group did not have a surveillance culture specimen obtained after enrollment in the resistance substudy.
These women were excluded from all subsequent analyses. During the follow-up period, a total of 438 vaginal surveillance culture specimens were obtained from 88 women assigned fluconazole, and 434 surveillance culture specimens were obtained from the 79 women assigned placebo. The majority of women had у5 surveillance cultures analyzed. While receiving blinded medication, 72 women assigned fluconazole had 302 vaginal surveillance culture specimens obtained and 56 women receiving placebo had 218 surveillance culture specimens obtained after their enrollment in the substudy.
In Vitro Susceptibility Studies
Per-patient analyses. Table 2 summarizes in vitro susceptibility to fluconazole in a per-patient, intention-to-treat analysis. In addition, the number and percentage of patients from whom at least 1 isolate was recovered that demonstrated either resistance (MIC, у64 mg/mL) or DD-S (MIC, у16 mg/mL) to fluconazole were also tabulated.
Fluconazole-resistant isolates of any species were recovered from 11 patients (12.5%) assigned fluconazole and 6 patients Table 2 . Intention-to-treat analysis of patients whose cultures yielded у1 isolate with an MIC of у64 mg/mL (resistant) or у16 mg/mL (dose-dependent susceptible), according to the organism isolated. (8%) assigned placebo ( ). One patient assigned flucon-P p .32 azole had resistant Candida glabrata and C. albicans isolates recovered ∼1.5 years apart. C. glabrata was recovered from 15 of the 17 patients (11 fluconazole recipients vs. 4 placebo recipients;
). Only 3 fluconazole-resistant C. albicans iso-P p .11 lates were recovered during the substudy (1 in the fluconazole group and 2 in the placebo group;
). It is noteworthy P p .60 that of the patients whose isolates were fluconazole-resistant, 4 of the 6 patients assigned to the placebo group and 6 of the 11 assigned to the fluconazole group were receiving open-label fluconazole at the time the resistant phenotype was recovered. The remaining patients (2 in the placebo group and 5 in the fluconazole group) were receiving blinded medication.
Eighteen patients (20%) assigned fluconazole and 15 (19%) assigned placebo ( ) had at least 1 Candida isolate re-P p .85 covered with an MIC of fluconazole of у16 mg/mL. C. glabrata was the most common species isolated from women who had at least 1 strain recovered with an MIC of у16 mg/mL (16 fluconazole recipients vs. 10 placebo recipients;
). The per-P p .40 centage of women whose strains were resistant to fluconazole did not vary at any of the 9 participating sites ( ). P p .67 Seven of the 15 patients in the placebo group and 8 of the 18 patients in the fluconazole group had discontinued blinded study medication and had begun receiving open-label fluconazole before isolation of a yeast with an MIC of fluconazole of у16 mg/mL. Only 8 patients assigned fluconazole and 4 patients assigned placebo had a Candida isolate recovered with fluconazole resistance or DD-S during blinded therapy with the study drug. Two patients in the fluconazole group and 4 in the placebo group had Candida isolates recovered that were either resistant to fluconazole or DD-S but had no prior fluconazole exposure. Figure 1 summarizes the results of the in vitro susceptibility testing. The fluconazole group differed significantly from the placebo group with regard to the distributions of the MICs of fluconazole for C. albicans isolates ( ). Among those P p .003 patients assigned fluconazole, 5 (12%) had C. albicans isolates recovered that had an MIC of fluconazole of 0.25 mg/mL, and 20 (47%) had C. albicans isolates recovered with MICs of fluconazole of 0.5 mg/mL. In contrast, in the group assigned placebo, 25 (46%) of the women had C. albicans strains recovered with an MIC of fluconazole of 0.25 mg/mL, and 12 (22%) patients had C. albicans isolates recovered with an MIC of fluconazole of 0.5 mg/mL.
The MIC 50 of fluconazole for the non-albicans Candida species isolates was 8 mg/mL in both groups ( ). For C. P p .78 glabrata, the median MIC of fluconazole for those patients assigned fluconazole was 12 mg/mL, whereas the median MIC of fluconazole for those patients assigned placebo was 8 mg/ mL ( ). P p .48 Per-isolate analysis. Table 3 fluconazole. The remaining 140 C. albicans isolates (97%) were all susceptible to fluconazole.
As expected, the MICs of fluconazole were higher for nonalbicans Candida species than they were for C. albicans isolates. Twenty-one (16%) of 131 non-albicans Candida isolates were found to be resistant to fluconazole: 9 isolates (15%) were from patients who received blinded fluconazole, 1 (3%) was from a patient who received placebo, and 11 (29%) were from women who were taking open-label fluconazole. All 21 isolates were C. glabrata (21 [22%] of 97 C. glabrata isolates). In addition, 24 (18%) of the non-albicans Candida species had MICs of fluconazole in the DD-S range. Thus, 45 isolates had MICs of у16 mg/mL: 18 isolates (30%) were from patients who received blinded fluconazole, 5 (15%) were from patients who received placebo, and 22 (58%) were from patients who received openlabel fluconazole.
Analysis of antifungal cross-resistance. Overall, for all
Candida species, agreement in 3 categories (susceptibility, DD-S, and resistance) was 69% for itraconazole and fluconazole and 69% for clotrimazole and fluconazole. Nineteen (80%) of the 23 Candida isolates that were found to be resistant to fluconazole (8 of 9 from recipients of blinded fluconazole, 1 of 2 from recipients of placebo, and 10 of 12 from recipients of open-label fluconazole) were also found to be resistant to clotrimazole and itraconazole.
Of the 2 fluconazole-resistant C. albicans isolates recovered, 1 was resistant to clotrimazole and the other to fluconazoleitraconazole. Twenty-one fluconazole-resistant C. glabrata isolates were recovered. Two of these isolates demonstrated resistance to clotrimazole but not to itraconazole, whereas 19 isolates demonstrated multi-azole cross-resistance (fluconazole-clotrimazole-itraconazole). None of the non-albicans Candida species isolates demonstrated fluconazole resistance without also being resistant to another azole. Of the 50 isolates for which MICs were in the fluconazole resistance or DD-S range, none had MICs of itraconazole in the susceptibility range (MIC, !0.25 mg/mL). Moreover, only 2 (4%) of the 50 Candida isolates with an MIC of fluconazole of у16 mg/mL had MICs of clotrimazole of !0.25 mg/mL.
Of the 276 isolates evaluated, 9 were resistant to only itraconazole (8 isolates of C. glabrata and 1 isolate of Candida krusei); 8 were resistant to only clotrimazole (4 isolates of C. albicans and 4 isolates of C. glabrata); and 11 (all C. glabrata) displayed resistance to clotrimazole and itraconazole. A total of 51 isolates (31 recovered from patients assigned fluconazole and 20 from patients assigned placebo) demonstrated resistance to at least 1 azole. No amphotericin B or flucytosine resistance was identified in any of the 276 isolates recovered from either study group.
DISCUSSION
Several reports describing in vitro and clinical resistance to azoles developing during antifungal therapy have been published elsewhere [16, [22] [23] [24] [25] [26] [27] . In contrast, this study failed to demonstrate any differences in the in vitro fluconazole resistance between the 2 study groups. This may be due in part to A recent concern has been the recognition of multi-azole cross-resistance in Candida isolates recovered from patients who have refractory candidiasis [26] [27] [28] . In this study, there were only 2 C. albicans isolates with an MIC of fluconazole of у64 mg/mL: one had an MIC of clotrimazole of у1 mg/mL and the other had an MIC of itraconazole of у1 mg/mL. In contrast, there was substantial azole cross-resistance among the non-albicans Candida species isolates that were resistant to fluconazole.
As described in several previously published reports, in both of our groups the incidence of fluconazole resistance was higher among the non-albicans Candida species than it was among the C. albicans isolates. The higher incidence appears to be unrelated to treatment group, because patients in the placebo group also took fluconazole.
Although the estimated frequency of fluconazole resistance is still unknown, it is postulated to be ∼4%-5% among C. albicans isolates recovered from persons with AIDS [26, 27] . In this study we noted an incidence of fluconazole resistance of 1.5%-2% (3 of 167 patients and 2 of 199 isolates).
There are several limitations to consider when analyzing the results of this study. First, only vaginal specimens were routinely collected for surveillance analysis. Oral isolates were collected only from patients with documented candidiasis; this may have caused us to miss patients who were asymptomatic but who were colonized with resistant isolates in the oropharynx or esophagus. Second, most of our patients had CD4 ϩ cell counts of 1100 cells/mm 3 at study enrollment, whereas the majority of reports on antifungal resistance have described this problem in patient populations with CD4 ϩ cell counts of !50 cells/mm 3 . We cannot determine, on the basis of this study, whether open-label fluconazole selected for resistant organisms and led to more azole-resistant isolates. The increased frequency of azole-resistant Candida strains among women initially assigned placebo is likely to be multifactorial. The placebo group had a higher rate of mucosal candidiasis events and, thus, greater exposure to fluconazole, because it was frequently used to treat symptomatic mucosal candidiasis. Fluconazole was used more frequently in the placebo group, for both treatment of acute candidiasis and secondary prophylaxis; hence, the placebo group was also significantly exposed to fluconazole.
In summary, weekly fluconazole prophylaxis does not increase the incidence of azole resistance among the C. albicans isolates recovered from this patient population. Although the intention-to-treat analysis shows no difference in fluconazoleresistant Candida recovery between the 2 groups, this appears to be due to a much higher rate of resistance among women who took open-label fluconazole.
Despite the fact that we did not detect any differences in resistance patterns among the 2 treatment groups, we continue to believe that prophylaxis should be considered only for persons at high risk of developing recurrent mucosal candidiasis that affects their total well-being.
